Aspirin Improves Survival in HLA Class I–Expressing Colon Cancer
In a cohort study reported in JAMA Internal Medicine, Reimers et al found that aspirin use was associated with a significant 47% reduction in mortality risk after diagnosis of colon cancer expressing HLA class I antigen. There was no difference in aspirin benefit according to strong or weak prostaglandin endoperoxide synthase 2 (PTGS2) expression.
- Aspirin use after diagnosis was associated with a 47% reduction in mortality risk in patients with tumors expressing HLA class I antigen.
- Survival benefit with aspirin use was similar in patients with low or high PTGS2 expression.
Read the full article: Aspirin Improves Survival in HLA Class I–Expressing Colon Cancer